Overview

Safety and Efficacy of HydroLenz for Vitrectomy-Induced Lens Opacities

Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to provide safety data for two different dosages of HydroLenz. Secondary objectives are to provide preliminary data to determine whether HydroLenz has the same effect in humans as it does in the porcine model; to confirm the reliability of methods for evaluating lens opacity; and, to acquire information that can be used to design the pivotal study.
Phase:
Phase 1
Details
Lead Sponsor:
PromiSight, LLC